Indegene Acquires BioPharm Communications for $106 Million

Indegene Limited , a Bengaluru-based healthcare technology company, has acquired BioPharm Communications , a Pennsylvania-based marketing services agency and part of Omnicom Health Group , for up to $106 million . The acquisition was executed through Indegene’s U.S. subsidiary, ILSL Inc., and aims to expand Indegene’s commercialization and AdTech capabilities for global pharmaceutical companies. BioPharm, founded in 2005, reported revenues of $38.13 million in 2024 and has worked with 17 of the world’s 25 largest biopharma organizations. The agency provides strategy, planning, media operations, and campaign execution. Its work includes developing omnichannel campaigns that connect healthcare professionals with pharmaceutical companies through targeted media. By joining Indegene, BioPharm becomes part of a company already serving a wide base of global life sciences clients. Announcing the acquisition, Manish Gupta , chairman and chief executive officer of Indegene, said, “BioPharm has built an impressive growth flywheel, with advanced tech capabilities, deep therapeutic expertise, and long-standing client relationships. This acquisition reinforces our role as a commercialization partner for the life sciences industry, helping clients unlock greater strategic value from their marketing and AdTech investments.” Steve Carickhoff , president of BioPharm, added, “Indegene is a natural home for us, given their client-focused, innovation-first, employee-centric culture backed by strong technology platforms, data and analytics capabilities, deep medical expertise, marquee client base and a global delivery model. We are very excited to join the larger Indegene family at a pivotal time for the industry.” A Record of Targeted Acquisitions Indegene, founded in 1998, has grown its global operations through a combination of acquisitions and internal expansion. The company was publicly listed on Indian stock exchanges in 2025 and reported revenues of over INR 3,400 crore for FY 2023–24 . Previous acquisitions in the United States include CultHealth , a healthcare marketing agency acquired in 2021, and Medical Marketing Economics , a consultancy focused on pricing and market access. Integrating BioPharm adds a team with experience across therapeutic areas and long-standing client relationships. Omnicom Health Group’s decision to sell BioPharm is part of a broader restructuring in the healthcare communications sector. BioPharm’s work spans multiple pharmaceutical clients, delivering campaigns across digital and traditional media. Its teams bring knowledge of regulatory requirements, channel-specific engagement methods, and campaign execution processes. The integration of BioPharm adds to Indegene’s operational capacity in the United States and complements existing teams managing other international client portfolios. The combined operations will allow the company to oversee projects across multiple therapeutic areas, including oncology, cardiovascular, and rare diseases. By integrating BioPharm’s staff, Indegene adds expertise in campaign planning, media placement, and reporting processes. The acquisition enables both companies to retain ongoing programs for existing clients while expanding coverage of new campaigns. Shifting Models of Pharma Communication Pharmaceutical engagement has evolved in recent years. In-person visits by representatives are no longer the primary mode of communication, as healthcare professionals increasingly use digital and multichannel channels to receive information. A 2024 Deloitte survey noted that many consumers, including healthcare professionals, find virtual interactions more convenient BioPharm designs campaigns that show these preferences, including targeted outreach across multiple channels. Its approach includes planning, media placement, and measurement of campaign reach and effectiveness. Integrating BioPharm into Indegene’s operations allows the combined teams to continue managing campaigns across multiple channels for healthcare audiences. The acquisition, valued at $106 million, expands Indegene’s operations in North America. BioPharm’s staff, client relationships, and campaign experience strengthen Indegene’s delivery capabilities in the U.S. pharmaceutical market, where life sciences companies continue to invest in targeted communication with healthcare professionals.